This pharmacological feature of the GPR4 antagonist can be advantageous for the treatment of COVID-19, as the reduction in both viral load and hyperinflammatory response is necessary for optimal management of COVID-19 related complications (Sasaki et al., 2024; Li et al., 2023). Here, GPR4 is linked to COVID-19.